Your browser doesn't support javascript.
loading
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.
Baronciani, Luciano; Peake, Ian; Schneppenheim, Reinhard; Goodeve, Anne; Ahmadinejad, Minoo; Badiee, Zahra; Baghaipour, Mohammad-Reza; Benitez, Olga; Bodó, Imre; Budde, Ulrich; Cairo, Andrea; Castaman, Giancarlo; Eshghi, Peyman; Goudemand, Jenny; Hassenpflug, Wolf; Hoorfar, Hamid; Karimi, Mehran; Keikhaei, Bijan; Lassila, Riitta; Leebeek, Frank W G; Lopez Fernandez, Maria Fernanda; Mannucci, Pier Mannuccio; Marino, Renato; Niksic, Nikolas; Oyen, Florian; Santoro, Cristina; Tiede, Andreas; Toogeh, Gholamreza; Tosetto, Alberto; Trossaert, Marc; Zetterberg, Eva M K; Eikenboom, Jeroen; Federici, Augusto B; Peyvandi, Flora.
Afiliación
  • Baronciani L; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
  • Peake I; Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom.
  • Schneppenheim R; Department of Pediatric Hematology and Oncology, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany.
  • Goodeve A; Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom.
  • Ahmadinejad M; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
  • Badiee Z; Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.
  • Baghaipour MR; Hemophilia-Thalassemia Center, Mashhad University of Medical Science, Mashad, Islamic Republic of Iran.
  • Benitez O; Iranian Hemophilia Comprehensive Treatment Centre, Tehran, Islamic Republic of Iran.
  • Bodó I; Hemophilia Unit, University Vall d'Hebron Hospital, Barcelona, Spain.
  • Budde U; Department of Internal Medicine and Hematology-Semmelweis University, Budapest, Hungary.
  • Cairo A; Hemostaseology Medilys Laborgesellschaft mbH, Hamburg, Germany.
  • Castaman G; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
  • Eshghi P; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
  • Goudemand J; Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.
  • Hassenpflug W; Univ. Lille, CHU Lille, Haematology and Transfusion, Lille, France.
  • Hoorfar H; Department of Pediatric Hematology and Oncology, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany.
  • Karimi M; Hemophilia Center, Esfahan University of Medical Science, Esfahan, Islamic Republic of Iran.
  • Keikhaei B; Hematology Research Center, Shiraz University of Medical Science, Shiraz, Iran.
  • Lassila R; Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Leebeek FWG; Research Program Unit in Oncology, University of Helsinki, Helsinki University Central Hospital, Coagulation Disorders, Helsinki, Finland.
  • Lopez Fernandez MF; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Mannucci PM; Complejo Hospitalario Universitario de A Coruña-Servicio de Hematología y Hemoterapia, A Coruña, Spain.
  • Marino R; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
  • Niksic N; Hemophilia and Thrombosis Centre, University Hospital Policlinico, Bari, Italy.
  • Oyen F; Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom.
  • Santoro C; Department of Pediatric Hematology and Oncology, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany.
  • Tiede A; Hematology, Hemophilia and Thrombosis Center, University Hospital Policlinico Umberto I, Rome, Italy.
  • Toogeh G; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Tosetto A; Thrombosis Hemostasis Research Center-Vali-Asr Hospital-Emam Khameini Complex Hospital, Tehran University of Medical Science, Tehran, Islamic Republic of Iran.
  • Trossaert M; Hemophilia and Thrombosis Center, Hematology Department, San Bortolo Hospital, Vicenza, Italy.
  • Zetterberg EMK; Centre Régional de Traitement de l'Hémophilie-Laboratoire d'Hématologie, Nantes, France.
  • Eikenboom J; Skane University Hospital, Malmo, Sweden.
  • Federici AB; Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
  • Peyvandi F; Hematology and Transfusion Medicine, L. Sacco University Hospital, Department of Oncology and Oncohematology, University of Milan, Milan, Italy; and.
Blood Adv ; 5(15): 2987-3001, 2021 08 10.
Article en En | MEDLINE | ID: mdl-34351388
ABSTRACT
Type 3 von Willebrand disease (VWD3) is a rare and severe bleeding disorder characterized by often undetectable von Willebrand factor (VWF) plasma levels, a recessive inheritance pattern, and heterogeneous genotype. The objective of this study was to identify the VWF defects in 265 European and Iranian patients with VWD3 enrolled in 3WINTERS-IPS (Type 3 Von Willebrand International Registries Inhibitor Prospective Study). All analyses were performed in centralized laboratories. The VWF genotype was studied in 231 patients with available DNA (121 [115 families] from Europe [EU], and 110 [91 families] from Iran [IR]). Among 206 unrelated patients, 134 were homozygous (EU/IR = 57/77) and 50 were compound heterozygous (EU/IR = 43/7) for VWF variants. In 22 patients, no or only one variant was found. A total of 154 different VWF variants (EU/IR = 101/58 [5 shared]) were identified among the 379 affected alleles (EU/IR = 210/169), of which 48 (EU/IR = 18/30) were novel. The variants p.Arg1659*, p.Arg1853*, p.Arg2535*, p.Cys275Ser, and delEx1_Ex5 were found in both European and Iranian VWD3 patients. Sixty variants were identified only in a single allele (EU/IR = 50/10), whereas 18 were recurrent (≥3 patients) within 144 affected alleles. Nine large deletions and one large insertion were found. Although most variants predicted null alleles, 21% of patients carried at least 1 missense variant. VWD3 genotype was more heterogeneous in the European population than in the Iranian population, with nearly twice as many different variants. A higher number of novel variants were found in the Iranian VWD3 patients.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades de von Willebrand / Enfermedad de von Willebrand Tipo 3 Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Blood Adv Año: 2021 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades de von Willebrand / Enfermedad de von Willebrand Tipo 3 Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Blood Adv Año: 2021 Tipo del documento: Article País de afiliación: Italia